Steven Cohen's MYGN Position Overview
Steven Cohen (via Point72 Asset Management, L.P.) currently holds 1.23 M shares of Myriad Genetics, Inc. (MYGN) worth $7.58 M, representing 0.01% of the portfolio. First purchased in 2014-Q4, this long-term strategic position has been held for 36 quarters.
Based on 13F filings, Steven Cohen has maintained a strategic position in MYGN, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2017, adding 863,948 shares. Largest reduction occurred in Q3 2019, reducing 844,687 shares.
Analysis based on 13F filings available since 2013 Q2
Steven Cohen's Myriad Genetics (MYGN) Holding Value Over Time
Track share changes against reported price movement
Quarterly Myriad Genetics (MYGN) Trades by Steven Cohen
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +158,705 | Add 14.78% | 1.23 M | $6.15 |
| Q3 2025 | +535,903 | Add 99.60% | 1.07 M | $7.23 |
| Q2 2025 | +353,060 | Add 190.84% | 538,060 | $5.31 |
| Q1 2025 | -163,604 | Reduce 46.93% | 185,000 | $8.87 |
| Q4 2024 | -715,107 | Reduce 67.23% | 348,604 | $13.71 |
| Q3 2024 | +224,255 | Add 26.71% | 1.06 M | $27.39 |
| Q2 2024 | +61,260 | Add 7.87% | 839,456 | $24.46 |
| Q1 2024 | +778,196 | New Buy | 778,196 | $21.32 |
| Q4 2023 | -2,636 | Sold Out | 0 | $0.00 |
| Q3 2023 | +2,601 | Add 7431.43% | 2,636 | $16.04 |
| Q2 2023 | +35 | New Buy | 35 | $23.31 |
| Q1 2023 | -26,800 | Sold Out | 0 | $0.00 |
| Q4 2022 | -377,608 | Reduce 93.37% | 26,800 | $14.51 |
| Q3 2022 | +175,163 | Add 76.41% | 404,408 | $19.08 |
| Q2 2022 | +81,648 | Add 55.32% | 229,245 | $18.17 |
| Q1 2022 | +147,597 | New Buy | 147,597 | $25.20 |
| Q4 2021 | -239,493 | Sold Out | 0 | $0.00 |
| Q3 2021 | -142,312 | Reduce 37.27% | 239,493 | $32.29 |
| Q2 2021 | -16,043 | Reduce 4.03% | 381,805 | $30.58 |
| Q1 2021 | +28,740 | Add 7.79% | 397,848 | $30.45 |
| Q4 2020 | +345,029 | Add 1432.90% | 369,108 | $19.77 |
| Q3 2020 | +24,079 | New Buy | 24,079 | $13.04 |
| Q2 2020 | -141,500 | Sold Out | 0 | $0.00 |
| Q1 2020 | +124,839 | Add 749.29% | 141,500 | $14.31 |
| Q4 2019 | -121,253 | Reduce 87.92% | 16,661 | $27.25 |
| Q3 2019 | -844,687 | Reduce 85.96% | 137,914 | $28.63 |
| Q2 2019 | +359,488 | Add 57.69% | 982,601 | $27.78 |
| Q1 2019 | -313,394 | Reduce 33.46% | 623,113 | $33.20 |
| Q4 2018 | +326,187 | Add 53.45% | 936,507 | $29.07 |
| Q3 2018 | -225,880 | Reduce 27.01% | 610,320 | $46.00 |
| Q2 2018 | -46,674 | Reduce 5.29% | 836,200 | $37.37 |
| Q1 2018 | +18,926 | Add 2.19% | 882,874 | $29.55 |
| Q4 2017 | +863,948 | New Buy | 863,948 | $34.34 |
| Q2 2015 | -153,400 | Sold Out | 0 | $0.00 |
| Q1 2015 | -206,900 | Reduce 57.42% | 153,400 | $35.40 |
| Q4 2014 | +360,300 | New Buy | 360,300 | $34.06 |
Steven Cohen's Myriad Genetics Investment FAQs
Steven Cohen first purchased Myriad Genetics, Inc. (MYGN) in Q4 2014, acquiring 360,300 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen has held Myriad Genetics, Inc. (MYGN) for 36 quarters since Q4 2014.
Steven Cohen's largest addition to Myriad Genetics, Inc. (MYGN) was in Q4 2017, adding 863,948 shares worth $29.67 M.
According to the latest 13F filing for Q4 2025, Steven Cohen's firm, Point72 Asset Management, L.P., owns 1,232,668 shares of Myriad Genetics, Inc. (MYGN), valued at approximately $7.58 M.
As of the Q4 2025 filing, Myriad Genetics, Inc. (MYGN) represents approximately 0.01% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.
Steven Cohen's peak holding in Myriad Genetics, Inc. (MYGN) was 1,232,668 shares, as reported at the end of Q4 2025.